Navigation Links
PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy

Data Presented at 59th American Academy of Neurology Annual Meeting

BOSTON and SOUTH PLAINFIELD, N.J., May 04, 2007 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery and development of small-molecule drugs targeting post-transcriptional control processes, today announced positive interim data from a Phase 2 clinical trial of PTC124 in patients with Duchenne muscular dystrophy (DMD) due to a nonsense mutation. The results from the first two cohorts of the three-cohort study show that treatment with PTC124 was associated with increases in muscle dystrophin expression and reductions in serum creatinine kinase values in at least 50 percent of evaluable patients. These data were presented today at the 59th American Academy of Neurology (AAN) Annual Meeting.

Patients with DMD lack dystrophin, a protein that is critical to the structural stability of muscle fibers. This Phase 2 multi-site, open-label, dose-ranging clinical trial is evaluating muscle dystrophin expression in patients with nonsense-mutation-mediated DMD. Blood levels of muscle-derived creatine kinase are being measured as assessments of muscle integrity. PTC124 safety, compliance, and pharmacokinetics are also being evaluated.

"These data provide clinical evidence that PTC124 treatment may address the underlying cause of DMD," said Dr. Richard Finkel, Director of the Neuromuscular Program, Children's Hospital of Philadelphia, PA, who presented these results today at AAN as one of the trial's lead investigators. "Development of PTC124 offers the potential for a new therapeutic option for patients with DMD due to a nonsense mutation."

Langdon Miller, M.D., Chief Medical Officer of PTC, added, "We are very pleased with these additional pharmacologic proof-of-concept data from our short-term Phase 2 clinical trial of PTC124 in patients with DMD. Based on the growing body of Phase 2 clinic
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:6/1/2015)... The Middle Eastern MRI systems market is fast growing. MRI ... domains of medicine like cardiology, neurology and orthopedics. It is ... and is as safer tool as it does not use ... equipment into Open system, closed system and straight or upright ... as it is preferred over that currently common closed type ...
(Date:6/1/2015)... 1, 2015 Novel t ... growth , says   GBI Research ... treatment market will be driven primarily by the introduction of ... settings, which either replace or combine with generic chemotherapies. ... Non-Small Cell Lung Cancer Market to 2020 - forecasts ...
(Date:6/1/2015)... Symbiotix Biotherapies, Inc. ("Symbiotix") today announced that ... Business Technology Transfer (STTR) Program award from the National ... Infectious Diseases (NIAID). The company, based in ... molecular therapeutics from the human microbiome . ... is the first molecule to emerge from the microbiome ...
Breaking Medicine Technology:Middle East MRI Market - Growth, Trends And Forecasts (2014 - 2019) 2Middle East MRI Market - Growth, Trends And Forecasts (2014 - 2019) 3New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 2New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 3Symbiotix Biotherapies Announces $2.3 Million Award from NIH's National Institute of Allergy and Infectious Diseases (NIAID) 2
... CAMBRIDGE, Mass., May 15, 2012  IntelligentMDx (IMDx) announced today ... high-throughput, qualitative in vitro diagnostic test designed ... (GBS) for use in screening pregnant women and ... pathogen. GBS is responsible for life-threatening bacterial infections in ...
... 2012 Reportlinker.com announces that ... is available in its catalogue: ... Global Pharmaceutical Survey ... and Procurement Strategies in the ...
Cached Medicine Technology:IntelligentMDx Announces CE-Marking of a new high-throughput test for Group B Streptococcus intended to improve women's health and prenatal care 2Global Pharmaceutical Survey 2012-2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry 2Global Pharmaceutical Survey 2012-2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry 3Global Pharmaceutical Survey 2012-2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry 4Global Pharmaceutical Survey 2012-2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry 5Global Pharmaceutical Survey 2012-2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry 6Global Pharmaceutical Survey 2012-2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry 7Global Pharmaceutical Survey 2012-2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry 8Global Pharmaceutical Survey 2012-2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry 9Global Pharmaceutical Survey 2012-2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry 10Global Pharmaceutical Survey 2012-2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry 11Global Pharmaceutical Survey 2012-2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry 12Global Pharmaceutical Survey 2012-2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry 13Global Pharmaceutical Survey 2012-2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry 14Global Pharmaceutical Survey 2012-2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry 15Global Pharmaceutical Survey 2012-2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry 16Global Pharmaceutical Survey 2012-2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry 17Global Pharmaceutical Survey 2012-2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry 18
(Date:6/1/2015)... (PRWEB) June 01, 2015 Sharenote, a ... solutions for the Healthcare Industry this week in Louisiana. ... cities in four days to provide potential providers with ... improve profitability, and monitor risk within their network. ... choice and is being used by more than 250 ...
(Date:6/1/2015)... There’s never a good time to be ... non-emergency, minor illnesses. , As of June 1, OSF HealthCare ... medical care via the Internet. Patients throughout Illinois can access ... , “Everyone is busy. We know that getting in to ... want to make it easier,” said Jeffry Tillery, MD, Chief ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 Hexagon Geospatial ... which is a new cloud-based subscription service that provides ... GIS software. , Both ERDAS IMAGINE and ... through Producer Online, which offers a subscription model for ... organizations need to be able to quickly and easily ...
(Date:6/1/2015)... June 01, 2015 Good360 announced ... the Irene W. and C.B. Pennington Foundation, Louisiana’s ... board of directors. Bertman joins Good360 just before ... this summer. , "Bringing with her many years ... am thrilled that Lori is joining the Good360 ...
(Date:6/1/2015)... Triple C announced today that they will be featured ... year on RFD-TV. , From the humble, farm shop beginnings ... today’s full line of rugged products, Triple C, Inc. has ... , In this segment, American Farmer will explore how Triple ... in the tough conditions on North American ranches. Viewers will ...
Breaking Medicine News(10 mins):Health News:OSF HealthCare Now Offering OSF OnCall 2Health News:OSF HealthCare Now Offering OSF OnCall 3Health News:Hexagon Geospatial Launches Cloud-Based Producer Online Suite 2Health News:Hexagon Geospatial Launches Cloud-Based Producer Online Suite 3Health News:Lori Bertman Joins Good360 Board of Directors 2Health News:Triple C to Be Featured in Upcoming Episode of American Farmer 2
... to a research that was published in Nature, certain ... roundworm Caenorhabditis// elegans also decrease the growth of tumors ... cancer risk increases as we grow older, and may ... Professor Cynthia Kenyon and colleagues from the University of ...
... Tobacco in all forms - whether smoked or chewed first ... a new study.//, ,Koon K. Teo and colleagues at ... 27,000 people in 52 countries for evidence that tobacco use ... health magazine WebMD., ,Previous medical research has determined that ...
... lost their parents and dear ones in the December 2004 ... new report.//, ,"Battered Islands" - the report of a ... - says a large number of children continue to suffer ... boy, was barely a few days old when the devastating ...
... Two studies have arrived at conflicting results on whether ... are published in the August// issue of the journal ... International Journal of Sport Nutrition and Exercise Metabolism. ... which manufactures Gatorade, found that protein in sports drinks ...
... that ordinary human brain cells could have the capacity that ... ,The scientists from the UF's McKnight Brain ... journal Development, explained in detail as to how they used ... patients to generate new brain tissue in mice. ...
... been published in the Emergency Medicine Journal, a study conducted ... patients admitted in emergency care have gone up well above ... in the past 5 years. ,The report ... absolute numbers of women who are intoxicated have almost doubled. ...
Cached Medicine News:Health News:Long-life genes - A new way to combat cancer… 2Health News:Long-life genes - A new way to combat cancer… 3Health News:Post-tsunami trauma still haunts children 2Health News:Human Brain Cells Might Have The Self Potential For Healing 2Health News:Human Brain Cells Might Have The Self Potential For Healing 3
The pocket-size Invacare Digit finger pulse oximeter is a convenient and economical solution to fast, reliable SpO2, pulse rate and pulse strength measurements. Its compact size is ideal for home use...
The Dolphin Medical 2150 Pulse Oximeter consists of the Dolphin ONE OEM 701 Module technology, (1) extension cable, and (1) oximetry sensor to non-invasively calculate the functional saturation of ar...
The SportStat Pulse Oximeter shines red and infrared light through a finger and detects the fluctuating signals caused by blood flow. Pulse rate is determined from the signals received by a light det...
The reliable and easy-to-use 3900/P pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
Medicine Products: